InnovaRx Innova Health Strategies

D72.19

Other eosinophilia

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 15 never code together
D72code
Excludes1
  • basophilia (D72.824)D72.824
  • immunity disorders (D80-D89)D80-D89
  • neutropenia (D70)D70
  • preleukemia (syndrome) (D46.9)D46.9
D72.1code
Excludes2
  • Löffler's syndrome (J82.89)J82.89
  • pulmonary eosinophilia (J82.-)J82.-
D50-D89chapter
Excludes2
  • autoimmune disease (systemic) NOS (M35.9)M35.9
  • certain conditions originating in the perinatal period (P00-P96)P00-P96
  • complications of pregnancy, childbirth and the puerperium (O00-O9A)O00-O9A
  • congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)Q00-Q99
  • endocrine, nutritional and metabolic diseases (E00-E88)E00-E88
  • human immunodeficiency virus [HIV] disease (B20)B20
  • injury, poisoning and certain other consequences of external causes (S00-T88)S00-T88
  • neoplasms (C00-D49)C00-D49
  • symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)R00-R94

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 2
D72.19code
Inclusion terms
  • Familial eosinophilia
  • Hereditary eosinophilia
Index entries leading here 2
Alongside this code 4 same parent — D72.1
Medications 2

MED-RT files conditions by MeSH, which carves the world differently from ICD-10. These are name matches on this code's description, offered as candidates — not as an assertion that they are this code.

Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

Maps to no condition category in any loaded model.

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
D72.1
Block
D70-D77
Siblings
4

Present FY2024–FY2027.